Your browser doesn't support javascript.
loading
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
Kissling, Esther; Hooiveld, Mariette; Sandonis Martín, Virginia; Martínez-Baz, Iván; William, Naoma; Vilcu, Ana-Maria; Mazagatos, Clara; Domegan, Lisa; de Lusignan, Simon; Meijer, Adam; Machado, Ausenda; Brytting, Mia; Casado, Itziar; Murray, Josephine-L K; Belhillil, Sylvie; Larrauri, Amparo; O'Donnell, Joan; Tsang, Ruby; de Lange, Marit; Rodrigues, Ana Paula; Riess, Maximilian; Castilla, Jesús; Hamilton, Mark; Falchi, Alessandra; Pozo, Francisco; Dunford, Linda; Cogdale, Jade; Jansen, Tessa; Guiomar, Raquel; Enkirch, Theresa; Burgui, Cristina; Sigerson, Debbie; Blanchon, Thierry; Martínez Ochoa, Eva María; Connell, Jeff; Ellis, Joanna; van Gageldonk-Lafeber, Rianne; Kislaya, Irina; Rose, Angela Mc; Valenciano, Marta.
  • Kissling E; Epiconcept, Paris, France.
  • Hooiveld M; Nivel, Utrecht, the Netherlands.
  • Sandonis Martín V; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Martínez-Baz I; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.
  • William N; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Vilcu AM; Public Health Scotland, Glasgow, Scotland.
  • Mazagatos C; INSERM, Sorbonne Université, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
  • Domegan L; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • de Lusignan S; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Meijer A; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
  • Machado A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Brytting M; Royal College of General Practitioners Research and Surveillance Centre, London, UK.
  • Casado I; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Murray JK; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
  • Belhillil S; The Public Health Agency of Sweden, Stockholm, Sweden.
  • Larrauri A; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.
  • O'Donnell J; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Tsang R; Public Health Scotland, Glasgow, Scotland.
  • de Lange M; Unité de Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut Pasteur, Paris, France.
  • Rodrigues AP; CNR des virus des infections respiratoires, Institut Pasteur, Paris, France.
  • Riess M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Castilla J; National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
  • Hamilton M; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland.
  • Falchi A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Pozo F; Royal College of General Practitioners Research and Surveillance Centre, London, UK.
  • Dunford L; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Cogdale J; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
  • Jansen T; The Public Health Agency of Sweden, Stockholm, Sweden.
  • Guiomar R; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.
  • Enkirch T; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
  • Burgui C; Public Health Scotland, Glasgow, Scotland.
  • Sigerson D; Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.
  • Blanchon T; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.
  • Martínez Ochoa EM; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
  • Connell J; Public Health England, London, England.
  • Ellis J; Nivel, Utrecht, the Netherlands.
  • van Gageldonk-Lafeber R; Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
  • Kislaya I; The Public Health Agency of Sweden, Stockholm, Sweden.
  • Rose AM; Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain.
  • Valenciano M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Euro Surveill ; 26(29)2021 07.
Article en En | MEDLINE | ID: mdl-34296676
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Adult / Aged / Humans País como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Adult / Aged / Humans País como asunto: Europa Idioma: En Año: 2021 Tipo del documento: Article